182 related articles for article (PubMed ID: 28730569)
21. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
22. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
Jung JH; Kim CY; Son SH; Kim DH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2015; 10(12):e0144152. PubMed ID: 26636824
[TBL] [Abstract][Full Text] [Related]
23. Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid.
Gogali F; Paterakis G; Rassidakis GZ; Kaltsas G; Liakou CI; Gousis P; Neonakis E; Manoussakis MN; Liapi C
J Clin Endocrinol Metab; 2012 May; 97(5):1474-82. PubMed ID: 22399513
[TBL] [Abstract][Full Text] [Related]
24. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for ipsilateral or contralateral central lymph node metastasis in unilateral papillary thyroid carcinoma.
Koo BS; Choi EC; Yoon YH; Kim DH; Kim EH; Lim YC
Ann Surg; 2009 May; 249(5):840-4. PubMed ID: 19387316
[TBL] [Abstract][Full Text] [Related]
26. Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults.
Gupta S; Patel A; Folstad A; Fenton C; Dinauer CA; Tuttle RM; Conran R; Francis GL
J Clin Endocrinol Metab; 2001 Mar; 86(3):1346-54. PubMed ID: 11238531
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for persistent disease in papillary thyroid carcinoma with lymph node metastasis.
Oral A; Yazici B; Akgün A; Hassoy H; Özcan Z
Nucl Med Commun; 2016 Jul; 37(7):721-6. PubMed ID: 26967062
[TBL] [Abstract][Full Text] [Related]
29. Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma.
Seo JW; Han K; Lee J; Kim EK; Moon HJ; Yoon JH; Park VY; Baek HM; Kwak JY
PLoS One; 2018; 13(3):e0193883. PubMed ID: 29509799
[TBL] [Abstract][Full Text] [Related]
30. Predictors of metastasis to lymph nodes posterior to the right recurrent laryngeal nerve in differentiated thyroid carcinoma: A prospective study.
Liu Z; Sun M; Xiao Y; Yang J; Zhang T; Zhao Y
Asian J Surg; 2017 Jul; 40(4):270-277. PubMed ID: 26948300
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of MiR-431 expression associated with lymph node metastasis and promotes cell invasion in papillary thyroid carcinoma.
Liu Y; Li L; Liu Z; Yuan Q; Lu X
Cancer Biomark; 2018; 22(4):727-732. PubMed ID: 29945344
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of cytokeratin 17 is associated with the development of papillary thyroid carcinoma and the presence of lymph node metastasis.
Kim HS; Lee JJ; Do SI; Kim K; Do IG; Kim DH; Chae SW; Sohn JH
Int J Clin Exp Pathol; 2015; 8(5):5695-701. PubMed ID: 26191283
[TBL] [Abstract][Full Text] [Related]
33. Lymph node characteristics for predicting locoregional recurrence of papillary thyroid cancer in adolescents and young adults.
Sun Y; Liu X; Ouyang W; Feng H; Wu J; Chen P; Wang J
Oral Oncol; 2017 Mar; 66():22-27. PubMed ID: 28249644
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of microscopic extrathyroidal extension in patients with papillary thyroid carcinoma.
Park JS; Chang JW; Liu L; Jung SN; Koo BS
Oral Oncol; 2017 Sep; 72():183-187. PubMed ID: 28222967
[TBL] [Abstract][Full Text] [Related]
35. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
[TBL] [Abstract][Full Text] [Related]
36. Occult contralateral central lymph node metastases in papillary thyroid carcinoma with unilateral lymph node metastasis in the lateral neck.
Koo BS; Choi EC; Park YH; Kim EH; Lim YC
J Am Coll Surg; 2010 Jun; 210(6):895-900. PubMed ID: 20510797
[TBL] [Abstract][Full Text] [Related]
37. Risk factors and indication for dissection of right paraesophageal lymph node metastasis in papillary thyroid carcinoma.
Zhang L; Liu H; Xie Y; Xia Y; Zhang B; Shan G; Li X
Eur J Surg Oncol; 2016 Jan; 42(1):81-6. PubMed ID: 26615455
[TBL] [Abstract][Full Text] [Related]
38. Occult lymph node metastasis and risk of regional recurrence in papillary thyroid cancer after bilateral prophylactic central neck dissection: A multi-institutional study.
Lee YC; Na SY; Park GC; Han JH; Kim SW; Eun YG
Surgery; 2017 Feb; 161(2):465-471. PubMed ID: 27574773
[TBL] [Abstract][Full Text] [Related]
39. Pattern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: a prospective study.
Nam IC; Park JO; Joo YH; Cho KJ; Kim MS
Head Neck; 2013 Jan; 35(1):40-5. PubMed ID: 22266805
[TBL] [Abstract][Full Text] [Related]
40. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
Walts AE; Mirocha JM; Bose S
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
